Detalhe da pesquisa
1.
[Detection of the BCR-ABL fusion: Comparative analysis of six commercially available FISH fusion probes]. / Detektion der BCR-ABL-Fusion : Vergleichende Analyse sechs kommerzieller FISH-Sondensätze.
Pathologe
; 36(4): 372-84, 2015 Jul.
Artigo
em Alemão
| MEDLINE | ID: mdl-26175197
2.
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
Leukemia
; 31(4): 889-895, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27774990
3.
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Leukemia
; 31(11): 2398-2406, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28804124
4.
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
Leukemia
; 29(5): 1123-32, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25676422
5.
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
Leukemia
; 28(10): 1988-92, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24798484
6.
[Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms]. / Neue Therapiestrategien für BCR/ABL-negative myeloproliferative Neoplasien.
Dtsch Med Wochenschr
; 137(42): 2171-8, 2012 Oct.
Artigo
em Alemão
| MEDLINE | ID: mdl-23055361
7.
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Leukemia
; 26(9): 2096-102, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22446502
8.
DNMT3A mutations in myeloproliferative neoplasms.
Leukemia
; 25(7): 1217-9, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21537334